ID   ERBB2_HUMAN             Reviewed;        1255 AA.
AC   P04626; B2RZG3; B4DHN3; Q14256; Q6LDV1; Q9UMK4; X5D2V5;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   12-OCT-2022, entry version 265.
DE   RecName: Full=Receptor tyrosine-protein kinase erbB-2;
DE            EC=2.7.10.1;
DE   AltName: Full=Metastatic lymph node gene 19 protein;
DE            Short=MLN 19;
DE   AltName: Full=Proto-oncogene Neu;
DE   AltName: Full=Proto-oncogene c-ErbB-2;
DE   AltName: Full=Tyrosine kinase-type cell surface receptor HER2;
DE   AltName: Full=p185erbB2;
DE   AltName: CD_antigen=CD340;
DE   Flags: Precursor;
GN   Name=ERBB2; Synonyms=HER2, MLN19, NEU, NGL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3003577; DOI=10.1038/319230a0;
RA   Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N.,
RA   Saito T., Toyoshima K.;
RT   "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal
RT   growth factor receptor.";
RL   Nature 319:230-234(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT ALA-1170.
RX   PubMed=2999974; DOI=10.1126/science.2999974;
RA   Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J.,
RA   Seeburg P.H., Libermann T.A., Schlessinger J., Francke U., Levinson A.,
RA   Ullrich A.;
RT   "Tyrosine kinase receptor with extensive homology to EGF receptor shares
RT   chromosomal location with neu oncogene.";
RL   Science 230:1132-1139(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-452; VAL-655 AND
RP   ALA-1170.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K., Sugiyama A.,
RA   Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y., Kumagai A., Oishi Y.,
RA   Yamamoto S., Ono Y., Komori Y., Yamazaki M., Kisu Y., Nishikawa T.,
RA   Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project focused on splicing variants.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-191 (ISOFORM 1).
RX   PubMed=3039351; DOI=10.1128/mcb.7.7.2597-2601.1987;
RA   Tal M., King C.R., Kraus M.H., Ullrich A., Schlessinger J., Givol D.;
RT   "Human HER2 (neu) promoter: evidence for multiple mechanisms for
RT   transcriptional initiation.";
RL   Mol. Cell. Biol. 7:2597-2601(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-867 (ISOFORM 6).
RC   TISSUE=Fetal brain;
RX   PubMed=24722188; DOI=10.1038/ncomms4650;
RA   Corominas R., Yang X., Lin G.N., Kang S., Shen Y., Ghamsari L., Broly M.,
RA   Rodriguez M., Tam S., Wanamaker S.A., Fan C., Yi S., Tasan M., Lemmens I.,
RA   Kuang X., Zhao N., Malhotra D., Michaelson J.J., Vacic V., Calderwood M.A.,
RA   Roth F.P., Tavernier J., Horvath S., Salehi-Ashtiani K., Korkin D.,
RA   Sebat J., Hill D.E., Hao T., Vidal M., Iakoucheva L.M.;
RT   "Protein interaction network of alternatively spliced isoforms from brain
RT   links genetic risk factors for autism.";
RL   Nat. Commun. 5:3650-3650(2014).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 737-1031.
RX   PubMed=2995967; DOI=10.1073/pnas.82.19.6497;
RA   Semba K., Kamata N., Toyoshima K., Yamamoto T.;
RT   "A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-
RT   1/epidermal growth factor-receptor gene and is amplified in a human
RT   salivary gland adenocarcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:6497-6501(1985).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 832-909.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=2992089; DOI=10.1126/science.2992089;
RA   King C.R., Kraus M.H., Aaronson S.A.;
RT   "Amplification of a novel v-erbB-related gene in a human mammary
RT   carcinoma.";
RL   Science 229:974-976(1985).
RN   [11]
RP   NUCLEOTIDE SEQUENCE OF 1081-1245, AND VARIANT ALA-1170.
RX   PubMed=8104414; DOI=10.1089/dna.1993.12.611;
RA   Sarkar F.H., Ball D.E., Li Y.W., Crissman J.D.;
RT   "Molecular cloning and sequencing of an intron of Her-2/neu (ERBB2) gene.";
RL   DNA Cell Biol. 12:611-615(1993).
RN   [12]
RP   INTERACTION WITH ERBB4, AND FUNCTION IN ACTIVATION OF STAT5A.
RX   PubMed=10358079; DOI=10.1074/jbc.274.24.17209;
RA   Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E.;
RT   "ErbB receptor-induced activation of stat transcription factors is mediated
RT   by Src tyrosine kinases.";
RL   J. Biol. Chem. 274:17209-17218(1999).
RN   [13]
RP   IDENTIFICATION IN A COMPLEX WITH PIK3C2A AND EGFR, IDENTIFICATION IN A
RP   COMPLEX WITH PIK3C2B AND EGFR, AND INTERACTION WITH PIK3C2B.
RX   PubMed=10805725; DOI=10.1128/mcb.20.11.3817-3830.2000;
RA   Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D.,
RA   Domin J.;
RT   "Class II phosphoinositide 3-kinases are downstream targets of activated
RT   polypeptide growth factor receptors.";
RL   Mol. Cell. Biol. 20:3817-3830(2000).
RN   [14]
RP   INTERACTION WITH MUC1.
RX   PubMed=12939402;
RA   Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.;
RT   "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent
RT   on the DF3/MUC1 oncoprotein.";
RL   Mol. Cancer Res. 1:765-775(2003).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=15380516; DOI=10.1016/j.ccr.2004.07.012;
RA   Wang S.C., Lien H.C., Xia W., Chen I.F., Lo H.W., Wang Z., Ali-Seyed M.,
RA   Lee D.F., Bartholomeusz G., Ou-Yang F., Giri D.K., Hung M.C.;
RT   "Binding at and transactivation of the COX-2 promoter by nuclear tyrosine
RT   kinase receptor ErbB-2.";
RL   Cancer Cell 6:251-261(2004).
RN   [16]
RP   INTERACTION WITH PLXNB1.
RX   PubMed=15210733; DOI=10.1083/jcb.200312094;
RA   Swiercz J.M., Kuner R., Offermanns S.;
RT   "Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine
RT   kinase ErbB-2.";
RL   J. Cell Biol. 165:869-880(2004).
RN   [17]
RP   INTERACTION WITH MEMO1.
RX   PubMed=15156151; DOI=10.1038/ncb1134;
RA   Marone R., Hess D., Dankort D., Muller W.J., Hynes N.E., Badache A.;
RT   "Memo mediates ErbB2-driven cell motility.";
RL   Nat. Cell Biol. 6:515-522(2004).
RN   [18]
RP   SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, AND INTERACTION WITH
RP   KPNB1; RANBP2; CRM1; EEA1 AND CLTC.
RX   PubMed=16314522; DOI=10.1128/mcb.25.24.11005-11018.2005;
RA   Giri D.K., Ali-Seyed M., Li L.Y., Lee D.F., Ling P., Bartholomeusz G.,
RA   Wang S.C., Hung M.C.;
RT   "Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell
RT   surface receptor.";
RL   Mol. Cell. Biol. 25:11005-11018(2005).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1248, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [20]
RP   FUNCTION, ALTERNATIVE INITIATION (ISOFORMS 2 AND 3), SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS OF MET-611; MET-687; MET-706 AND MET-712.
RX   PubMed=16794579; DOI=10.1038/sj.emboj.7601191;
RA   Anido J., Scaltriti M., Bech Serra J.J., Santiago Josefat B., Todo F.R.,
RA   Baselga J., Arribas J.;
RT   "Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative
RT   initiation of translation.";
RL   EMBO J. 25:3234-3244(2006).
RN   [21]
RP   INTERACTION WITH ERBB4, AND AUTOPHOSPHORYLATION IN TRANS.
RX   PubMed=16978839; DOI=10.1016/j.cellsig.2006.07.020;
RA   Li Z., Mei Y., Liu X., Zhou M.;
RT   "Neuregulin-1 only induces trans-phosphorylation between ErbB receptor
RT   heterodimer partners.";
RL   Cell. Signal. 19:466-471(2007).
RN   [22]
RP   PHOSPHORYLATION AT TYR-1248.
RX   PubMed=17554007; DOI=10.1523/jneurosci.5381-06.2007;
RA   Deng S., Hirschberg A., Worzfeld T., Penachioni J.Y., Korostylev A.,
RA   Swiercz J.M., Vodrazka P., Mauti O., Stoeckli E.T., Tamagnone L.,
RA   Offermanns S., Kuner R.;
RT   "Plexin-B2, but not Plexin-B1, critically modulates neuronal migration and
RT   patterning of the developing nervous system in vivo.";
RL   J. Neurosci. 27:6333-6347(2007).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   INTERACTION WITH PTK6, AND ACTIVITY REGULATION.
RX   PubMed=18719096; DOI=10.1073/pnas.0805009105;
RA   Xiang B., Chatti K., Qiu H., Lakshmi B., Krasnitz A., Hicks J., Yu M.,
RA   Miller W.T., Muthuswamy S.K.;
RT   "Brk is coamplified with ErbB2 to promote proliferation in breast cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12463-12468(2008).
RN   [26]
RP   FUNCTION IN NUCLEUS.
RX   PubMed=19372587; DOI=10.1158/1541-7786.mcr-08-0316;
RA   Hawthorne V.S., Huang W.C., Neal C.L., Tseng L.M., Hung M.C., Yu D.;
RT   "ErbB2-mediated Src and signal transducer and activator of transcription 3
RT   activation leads to transcriptional up-regulation of p21Cip1 and
RT   chemoresistance in breast cancer cells.";
RL   Mol. Cancer Res. 7:592-600(2009).
RN   [27]
RP   INTERACTION WITH CPNE3.
RX   PubMed=20010870; DOI=10.1038/onc.2009.456;
RA   Heinrich C., Keller C., Boulay A., Vecchi M., Bianchi M., Sack R.,
RA   Lienhard S., Duss S., Hofsteenge J., Hynes N.E.;
RT   "Copine-III interacts with ErbB2 and promotes tumor cell migration.";
RL   Oncogene 29:1598-1610(2010).
RN   [28]
RP   FUNCTION.
RX   PubMed=20937854; DOI=10.1073/pnas.1000975107;
RA   Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.;
RT   "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the
RT   plasma membrane of migrating cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1107, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [30]
RP   CHROMOSOMAL REARRANGEMENT WITH CDK12.
RX   PubMed=21097718; DOI=10.1158/0008-5472.can-10-1749;
RA   Zang Z.J., Ong C.K., Cutcutache I., Yu W., Zhang S.L., Huang D., Ler L.D.,
RA   Dykema K., Gan A., Tao J., Lim S., Liu Y., Futreal P.A., Grabsch H.,
RA   Furge K.A., Goh L.K., Rozen S., Teh B.T., Tan P.;
RT   "Genetic and structural variation in the gastric cancer kinome revealed
RT   through targeted deep sequencing.";
RL   Cancer Res. 71:29-39(2011).
RN   [31]
RP   FUNCTION IN NUCLEUS, INTERACTION WITH ACTB AND RPA194, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=21555369; DOI=10.1158/0008-5472.can-10-3504;
RA   Li L.Y., Chen H., Hsieh Y.H., Wang Y.N., Chu H.J., Chen Y.H., Chen H.Y.,
RA   Chien P.J., Ma H.T., Tsai H.C., Lai C.C., Sher Y.P., Lien H.C., Tsai C.H.,
RA   Hung M.C.;
RT   "Nuclear ErbB2 enhances translation and cell growth by activating
RT   transcription of ribosomal RNA genes.";
RL   Cancer Res. 71:4269-4279(2011).
RN   [32]
RP   INTERACTION WITH EGFR.
RX   PubMed=21190959; DOI=10.1210/en.2010-0940;
RA   Kharmate G., Rajput P.S., Watt H.L., Somvanshi R.K., Chaudhari N., Qiu X.,
RA   Kumar U.;
RT   "Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in
RT   the presence of somatostatin receptor 5 modulate signaling pathways.";
RL   Endocrinology 152:931-945(2011).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-182; SER-1054; SER-1083 AND
RP   THR-1166, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1054 AND SER-1151, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [36]
RP   INTERACTION WITH HSP90AA1 AND HSP90AB1.
RX   PubMed=26517842; DOI=10.1371/journal.pone.0141786;
RA   Prince T.L., Kijima T., Tatokoro M., Lee S., Tsutsumi S., Yim K., Rivas C.,
RA   Alarcon S., Schwartz H., Khamit-Kush K., Scroggins B.T., Beebe K.,
RA   Trepel J.B., Neckers L.;
RT   "Client proteins and small molecule inhibitors display distinct binding
RT   preferences for constitutive and stress-induced HSP90 isoforms and their
RT   conformationally restricted mutants.";
RL   PLoS ONE 10:E0141786-E0141786(2015).
RN   [37]
RP   PHOSPHORYLATION AT TYR-1112; TYR-1139; TYR-1196 AND TYR-1248, AND
RP   DEPHOSPHORYLATION BY PTPN12.
RX   PubMed=27134172; DOI=10.1016/j.celrep.2016.04.016;
RA   Li H., Yang F., Liu C., Xiao P., Xu Y., Liang Z., Liu C., Wang H., Wang W.,
RA   Zheng W., Zhang W., Ma X., He D., Song X., Cui F., Xu Z., Yi F., Sun J.P.,
RA   Yu X.;
RT   "Crystal structure and substrate specificity of PTPN12.";
RL   Cell Rep. 15:1345-1358(2016).
RN   [38]
RP   INTERACTION WITH SORL1, AND SUBCELLULAR LOCATION.
RX   PubMed=31138794; DOI=10.1038/s41467-019-10275-0;
RA   Pietilae M., Sahgal P., Peuhu E., Jaentti N.Z., Paatero I., Naervae E.,
RA   Al-Akhrass H., Lilja J., Georgiadou M., Andersen O.M., Padzik A., Sihto H.,
RA   Joensuu H., Blomqvist M., Saarinen I., Bostroem P.J., Taimen P., Ivaska J.;
RT   "SORLA regulates endosomal trafficking and oncogenic fitness of HER2.";
RL   Nat. Commun. 10:2340-2340(2019).
RN   [39]
RP   INTERACTION WITH SH3BGRL, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT
RP   TYR-877 AND TYR-1196.
RX   PubMed=32381043; DOI=10.1186/s13046-020-01577-z;
RA   Li H., Zhang M., Wei Y., Haider F., Lin Y., Guan W., Liu Y., Zhang S.,
RA   Yuan R., Yang X., Yang S., Wang H.;
RT   "SH3BGRL confers innate drug resistance in breast cancer by stabilizing
RT   HER2 activation on cell membrane.";
RL   J. Exp. Clin. Cancer Res. 39:81-81(2020).
RN   [40]
RP   SUBCELLULAR LOCATION.
RX   PubMed=34380438; DOI=10.1186/s12860-021-00379-1;
RA   Di Pisa F., Pesenti E., Bono M., Mazzarello A.N., Bernardi C.,
RA   Lisanti M.P., Renzone G., Scaloni A., Ciccone E., Fais F., Bruno S.,
RA   Scartezzini P., Ghiotto F.;
RT   "SH3BGRL3 binds to myosin 1c in a calcium dependent manner and modulates
RT   migration in the MDA-MB-231 cell line.";
RL   BMC Mol. Cell Biol. 22:41-41(2021).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 654-662 IN COMPLEX WITH HLA AND
RP   BETA-2 MICROGLOBULIN.
RX   PubMed=10593938; DOI=10.1074/jbc.274.51.36422;
RA   Kuhns J.J., Batalia M.A., Yan S., Collins E.J.;
RT   "Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of
RT   interactions with the center of the peptide.";
RL   J. Biol. Chem. 274:36422-36427(1999).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) OF 1247-1255 IN COMPLEX WITH ERBIN,
RP   AND INTERACTION WITH ERBIN.
RX   PubMed=12444095; DOI=10.1074/jbc.c200571200;
RA   Birrane G., Chung J., Ladias J.A.;
RT   "Novel mode of ligand recognition by the Erbin PDZ domain.";
RL   J. Biol. Chem. 278:1399-1402(2003).
RN   [43]
RP   STRUCTURE BY NMR OF 1135-1144 IN COMPLEX WITH GRB7, AND INTERACTION WITH
RP   GRB7.
RX   PubMed=12975581; DOI=10.1023/a:1025498409113;
RA   Ivancic M., Daly R.J., Lyons B.A.;
RT   "Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex and
RT   structural basis for Grb7 binding to ErbB2.";
RL   J. Biomol. NMR 27:205-219(2003).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 23-629 IN COMPLEX WITH THE
RP   ANTIBODY HERCEPTIN.
RX   PubMed=12610629; DOI=10.1038/nature01392;
RA   Cho H.-S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B.,
RA   Denney D.W. Jr., Leahy D.J.;
RT   "Structure of the extracellular region of HER2 alone and in complex with
RT   the Herceptin Fab.";
RL   Nature 421:756-760(2003).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE
RP   ANTIBODY PERTUZUMAB, INTERACTION WITH ERBB3, MUTAGENESIS OF
RP   317-LEU-HIS-318, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-187; ASN-259 AND
RP   ASN-530.
RX   PubMed=15093539; DOI=10.1016/s1535-6108(04)00083-2;
RA   Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M.,
RA   Sliwkowski M.X.;
RT   "Insights into ErbB signaling from the structure of the ErbB2-pertuzumab
RT   complex.";
RL   Cancer Cell 5:317-328(2004).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH THE
RP   ANTIBODY HERCEPTIN, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-259 AND
RP   ASN-530.
RX   PubMed=19299620; DOI=10.1126/science.1165480;
RA   Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K., Man W.,
RA   Peale F., Ross S., Wiesmann C., Fuh G.;
RT   "Variants of the antibody herceptin that interact with HER2 and VEGF at the
RT   antigen binding site.";
RL   Science 323:1610-1614(2009).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-646 IN COMPLEX WITH ENGINEERED
RP   ANTIBODY ZHER2, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-68; ASN-259 AND
RP   ASN-571.
RX   PubMed=20696930; DOI=10.1073/pnas.1005025107;
RA   Eigenbrot C., Ultsch M., Dubnovitsky A., Abrahmsen L., Hard T.;
RT   "Structural basis for high-affinity HER2 receptor binding by an engineered
RT   protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:15039-15044(2010).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 703-1029 IN COMPLEX WITH
RP   INHIBITOR SYR127063, CATALYTIC ACTIVITY, SUBUNIT, AND ACTIVITY REGULATION.
RX   PubMed=21454582; DOI=10.1074/jbc.m110.206193;
RA   Aertgeerts K., Skene R., Yano J., Sang B.C., Zou H., Snell G., Jennings A.,
RA   Iwamoto K., Habuka N., Hirokawa A., Ishikawa T., Tanaka T., Miki H.,
RA   Ohta Y., Sogabe S.;
RT   "Structural analysis of the mechanism of inhibition and allosteric
RT   activation of the kinase domain of HER2 protein.";
RL   J. Biol. Chem. 286:18756-18765(2011).
RN   [49]
RP   VARIANTS VAL-654 AND VAL-655.
RX   PubMed=8095488; DOI=10.1006/geno.1993.1081;
RA   Ehsani A., Low J., Wallace R.B., Wu A.M.;
RT   "Characterization of a new allele of the human ERBB2 gene by allele-
RT   specific competition hybridization.";
RL   Genomics 15:426-429(1993).
RN   [50]
RP   INVOLVEMENT IN CANCER, VARIANT GASC SER-776, VARIANT OC SER-857, VARIANT
RP   GLM LYS-914, AND VARIANTS LNCR PRO-755; ALA-TYR-VAL-MET-774 INS AND
RP   VAL-GLY-SER-779 INS.
RX   PubMed=15457249; DOI=10.1038/431525b;
RG   Cancer genome project and collaborative group;
RA   Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J.,
RA   Stevens C., O'Meara S., Smith R., Parker A., Barthorpe A., Blow M.,
RA   Brackenbury L., Butler A., Clarke O., Cole J., Dicks E., Dike A., Drozd A.,
RA   Edwards K., Forbes S., Foster R., Gray K., Greenman C., Halliday K.,
RA   Hills K., Kosmidou V., Lugg R., Menzies A., Perry J., Petty R., Raine K.,
RA   Ratford L., Shepherd R., Small A., Stephens Y., Tofts C., Varian J.,
RA   West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M.,
RA   Knowles M., Leung S.Y., Louis D.N., Looijenga L.H., Malkowicz B.,
RA   Pierotti M.A., Teh B., Chenevix-Trench G., Weber B.L., Yuen S.T.,
RA   Harris G., Goldstraw P., Nicholson A.G., Futreal P.A., Wooster R.,
RA   Stratton M.R.;
RT   "Lung cancer: intragenic ERBB2 kinase mutations in tumours.";
RL   Nature 431:525-526(2004).
RN   [51]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-654; VAL-655; SER-768; ALA-1170 AND
RP   ASP-1216, VARIANT GASC SER-776, AND VARIANT OC SER-857.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [52]
RP   INVOLVEMENT IN VSCN2, VARIANT VSCN2 VAL-710, CHARACTERIZATION OF VARIANT
RP   VSCN2 VAL-710, SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=33497358; DOI=10.1172/jci145837;
RA   Le T.L., Galmiche L., Levy J., Suwannarat P., Hellebrekers D.M.,
RA   Morarach K., Boismoreau F., Theunissen T.E., Lefebvre M., Pelet A.,
RA   Martinovic J., Gelot A., Guimiot F., Calleroz A., Gitiaux C., Hully M.,
RA   Goulet O., Chardot C., Drunat S., Capri Y., Bole-Feysot C., Nitschke P.,
RA   Whalen S., Mouthon L., Babcock H.E., Hofstra R., de Coo I.F., Tabet A.C.,
RA   Molina T.J., Keren B., Brooks A., Smeets H.J., Marklund U., Gordon C.T.,
RA   Lyonnet S., Amiel J., Bondurand N.;
RT   "Dysregulation of the NRG1/ERBB pathway causes a developmental disorder
RT   with gastrointestinal dysmotility in humans.";
RL   J. Clin. Invest. 131:0-0(2021).
CC   -!- FUNCTION: Protein tyrosine kinase that is part of several cell surface
CC       receptor complexes, but that apparently needs a coreceptor for ligand
CC       binding. Essential component of a neuregulin-receptor complex, although
CC       neuregulins do not interact with it alone. GP30 is a potential ligand
CC       for this receptor. Regulates outgrowth and stabilization of peripheral
CC       microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1
CC       signaling pathway elicits the phosphorylation and thus the inhibition
CC       of GSK3B at cell membrane. This prevents the phosphorylation of APC and
CC       CLASP2, allowing its association with the cell membrane. In turn,
CC       membrane-bound APC allows the localization of MACF1 to the cell
CC       membrane, which is required for microtubule capture and stabilization.
CC       {ECO:0000305}.
CC   -!- FUNCTION: In the nucleus is involved in transcriptional regulation.
CC       Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter
CC       and activates its transcription. Implicated in transcriptional
CC       activation of CDKN1A; the function involves STAT3 and SRC. Involved in
CC       the transcription of rRNA genes by RNA Pol I and enhances protein
CC       synthesis and cell growth. {ECO:0000269|PubMed:10358079,
CC       ECO:0000269|PubMed:15380516, ECO:0000269|PubMed:21555369}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:21454582};
CC   -!- ACTIVITY REGULATION: Activated by dimerization. Not activated by EGF,
CC       TGF-alpha and amphiregulin. Interaction with PTK6 increases its
CC       intrinsic kinase activity. {ECO:0000269|PubMed:18719096,
CC       ECO:0000269|PubMed:21454582}.
CC   -!- SUBUNIT: Homodimer (PubMed:21454582). Heterodimer with EGFR, ERBB3 and
CC       ERBB4 (PubMed:10358079, PubMed:15093539, PubMed:21190959,
CC       PubMed:16978839). Part of a complex with EGFR and either PIK3C2A or
CC       PIK3C2B. May interact with PIK3C2B when phosphorylated on Tyr-1196
CC       (PubMed:10805725). Interacts with PLXNB1 (PubMed:15210733). Interacts
CC       (when phosphorylated on Tyr-1248) with MEMO1 (PubMed:15156151).
CC       Interacts with MUC1; the interaction is enhanced by heregulin (HRG)
CC       (PubMed:12939402). Interacts (when phosphorylated on Tyr-1139) with
CC       GRB7 (via SH2 domain) (PubMed:12975581). Interacts (when phosphorylated
CC       on Tyr-1248) with ERBIN (PubMed:12444095). Interacts with KPNB1,
CC       RANBP2, EEA1, CRM1 and CLTC (PubMed:16314522). Interacts with PTK6
CC       (PubMed:18719096). Interacts with RPA194 and ACTB (PubMed:21555369).
CC       Interacts with PRKCABP, SRC and MYOC (By similarity). Interacts
CC       (preferentially with the tyrosine phosphorylated form) with CPNE3; this
CC       interaction occurs at the cell membrane and is increased in a growth
CC       factor heregulin-dependent manner (PubMed:20010870). Interacts with
CC       HSP90AA1 and HSP90AB1 in an ATP-dependent manner; the interaction
CC       suppresses ERBB2 kinase activity (PubMed:26517842). Interacts with
CC       SORL1; this interaction regulates ERBB2 subcellular distribution by
CC       promoting its recycling after internalization from endosomes back to
CC       the plasma membrane, hence stimulates ERBB2-mediated signaling
CC       (PubMed:31138794). Interacts with SH3BGRL (PubMed:32381043).
CC       {ECO:0000250|UniProtKB:P70424, ECO:0000269|PubMed:10358079,
CC       ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:12939402,
CC       ECO:0000269|PubMed:12975581, ECO:0000269|PubMed:15093539,
CC       ECO:0000269|PubMed:15156151, ECO:0000269|PubMed:15210733,
CC       ECO:0000269|PubMed:16314522, ECO:0000269|PubMed:16978839,
CC       ECO:0000269|PubMed:18719096, ECO:0000269|PubMed:20010870,
CC       ECO:0000269|PubMed:21190959, ECO:0000269|PubMed:21454582,
CC       ECO:0000269|PubMed:21555369, ECO:0000269|PubMed:26517842,
CC       ECO:0000269|PubMed:31138794, ECO:0000269|PubMed:32381043}.
CC   -!- INTERACTION:
CC       P04626; P00519: ABL1; NbExp=2; IntAct=EBI-641062, EBI-375543;
CC       P04626; P42684: ABL2; NbExp=6; IntAct=EBI-641062, EBI-1102694;
CC       P04626; P15309: ACP3; NbExp=2; IntAct=EBI-641062, EBI-1222012;
CC       P04626; P60709: ACTB; NbExp=10; IntAct=EBI-641062, EBI-353944;
CC       P04626; Q92625: ANKS1A; NbExp=2; IntAct=EBI-641062, EBI-1048612;
CC       P04626; O00213: APBB1; NbExp=2; IntAct=EBI-641062, EBI-81694;
CC       P04626; O75815: BCAR3; NbExp=2; IntAct=EBI-641062, EBI-702336;
CC       P04626; Q9HB71: CACYBP; NbExp=2; IntAct=EBI-641062, EBI-1047302;
CC       P04626; Q16543: CDC37; NbExp=5; IntAct=EBI-641062, EBI-295634;
CC       P04626; Q9NSE2: CISH; NbExp=4; IntAct=EBI-641062, EBI-617866;
CC       P04626; Q7Z7G1: CLNK; NbExp=2; IntAct=EBI-641062, EBI-7878194;
CC       P04626; P46109: CRKL; NbExp=2; IntAct=EBI-641062, EBI-910;
CC       P04626; Q93034: CUL5; NbExp=2; IntAct=EBI-641062, EBI-1057139;
CC       P04626; Q99704: DOK1; NbExp=2; IntAct=EBI-641062, EBI-1384360;
CC       P04626; Q8TEW6: DOK4; NbExp=2; IntAct=EBI-641062, EBI-6918542;
CC       P04626; Q15075: EEA1; NbExp=5; IntAct=EBI-641062, EBI-298113;
CC       P04626; P98172: EFNB1; NbExp=11; IntAct=EBI-641062, EBI-538287;
CC       P04626; P00533: EGFR; NbExp=25; IntAct=EBI-641062, EBI-297353;
CC       P04626; P04626: ERBB2; NbExp=12; IntAct=EBI-641062, EBI-641062;
CC       P04626; P21860: ERBB3; NbExp=29; IntAct=EBI-641062, EBI-720706;
CC       P04626; Q15303: ERBB4; NbExp=5; IntAct=EBI-641062, EBI-80371;
CC       P04626; Q9UJM3: ERRFI1; NbExp=4; IntAct=EBI-641062, EBI-2941912;
CC       P04626; P09769: FGR; NbExp=3; IntAct=EBI-641062, EBI-1383732;
CC       P04626; P06241: FYN; NbExp=2; IntAct=EBI-641062, EBI-515315;
CC       P04626; O75791: GRAP2; NbExp=2; IntAct=EBI-641062, EBI-740418;
CC       P04626; P62993: GRB2; NbExp=7; IntAct=EBI-641062, EBI-401755;
CC       P04626; Q14451: GRB7; NbExp=5; IntAct=EBI-641062, EBI-970191;
CC       P04626; P07900: HSP90AA1; NbExp=6; IntAct=EBI-641062, EBI-296047;
CC       P04626; P08238: HSP90AB1; NbExp=5; IntAct=EBI-641062, EBI-352572;
CC       P04626; P14625: HSP90B1; NbExp=2; IntAct=EBI-641062, EBI-359129;
CC       P04626; P11021: HSPA5; NbExp=3; IntAct=EBI-641062, EBI-354921;
CC       P04626; P46940: IQGAP1; NbExp=5; IntAct=EBI-641062, EBI-297509;
CC       P04626; P35568: IRS1; NbExp=2; IntAct=EBI-641062, EBI-517592;
CC       P04626; Q08881: ITK; NbExp=2; IntAct=EBI-641062, EBI-968552;
CC       P04626; P23458: JAK1; NbExp=2; IntAct=EBI-641062, EBI-1383438;
CC       P04626; Q14974: KPNB1; NbExp=14; IntAct=EBI-641062, EBI-286758;
CC       P04626; Q96JA1: LRIG1; NbExp=7; IntAct=EBI-641062, EBI-2865191;
CC       P04626; O75367: MACROH2A1; NbExp=6; IntAct=EBI-641062, EBI-2868511;
CC       P04626; O75367-3: MACROH2A1; NbExp=3; IntAct=EBI-641062, EBI-6250866;
CC       P04626; Q9UQF2: MAPK8IP1; NbExp=4; IntAct=EBI-641062, EBI-78404;
CC       P04626; Q13387: MAPK8IP2; NbExp=3; IntAct=EBI-641062, EBI-722813;
CC       P04626; P42679: MATK; NbExp=2; IntAct=EBI-641062, EBI-751664;
CC       P04626; Q9Y316: MEMO1; NbExp=6; IntAct=EBI-641062, EBI-1104564;
CC       P04626; O43639: NCK2; NbExp=2; IntAct=EBI-641062, EBI-713635;
CC       P04626; Q02297-7: NRG1; NbExp=2; IntAct=EBI-641062, EBI-2460927;
CC       P04626; O00750: PIK3C2B; NbExp=2; IntAct=EBI-641062, EBI-641107;
CC       P04626; P27986: PIK3R1; NbExp=12; IntAct=EBI-641062, EBI-79464;
CC       P04626; O00459: PIK3R2; NbExp=7; IntAct=EBI-641062, EBI-346930;
CC       P04626; Q92569: PIK3R3; NbExp=10; IntAct=EBI-641062, EBI-79893;
CC       P04626; P19174: PLCG1; NbExp=5; IntAct=EBI-641062, EBI-79387;
CC       P04626; P16885: PLCG2; NbExp=3; IntAct=EBI-641062, EBI-617403;
CC       P04626; O95602: POLR1A; NbExp=16; IntAct=EBI-641062, EBI-359472;
CC       P04626; Q13882: PTK6; NbExp=4; IntAct=EBI-641062, EBI-1383632;
CC       P04626; Q06124: PTPN11; NbExp=3; IntAct=EBI-641062, EBI-297779;
CC       P04626; Q05209: PTPN12; NbExp=4; IntAct=EBI-641062, EBI-2266035;
CC       P04626; Q99952: PTPN18; NbExp=6; IntAct=EBI-641062, EBI-1384210;
CC       P04626; Q99952-1: PTPN18; NbExp=5; IntAct=EBI-641062, EBI-12739708;
CC       P04626; P23467: PTPRB; NbExp=2; IntAct=EBI-641062, EBI-1265766;
CC       P04626; P08575: PTPRC; NbExp=2; IntAct=EBI-641062, EBI-1341;
CC       P04626; Q12913: PTPRJ; NbExp=2; IntAct=EBI-641062, EBI-2264500;
CC       P04626; Q15262: PTPRK; NbExp=2; IntAct=EBI-641062, EBI-474052;
CC       P04626; Q16827: PTPRO; NbExp=2; IntAct=EBI-641062, EBI-723739;
CC       P04626; Q15256: PTPRR; NbExp=2; IntAct=EBI-641062, EBI-2265659;
CC       P04626; P49792: RANBP2; NbExp=3; IntAct=EBI-641062, EBI-973138;
CC       P04626; P20936: RASA1; NbExp=8; IntAct=EBI-641062, EBI-1026476;
CC       P04626; O95980: RECK; NbExp=4; IntAct=EBI-641062, EBI-2823742;
CC       P04626; Q9NP31: SH2D2A; NbExp=2; IntAct=EBI-641062, EBI-490630;
CC       P04626; P29353: SHC1; NbExp=11; IntAct=EBI-641062, EBI-78835;
CC       P04626; P98077: SHC2; NbExp=3; IntAct=EBI-641062, EBI-7256023;
CC       P04626; Q92529: SHC3; NbExp=2; IntAct=EBI-641062, EBI-79084;
CC       P04626; Q9H6Q3: SLA2; NbExp=2; IntAct=EBI-641062, EBI-1222854;
CC       P04626; O15524: SOCS1; NbExp=2; IntAct=EBI-641062, EBI-968198;
CC       P04626; P12931: SRC; NbExp=11; IntAct=EBI-641062, EBI-621482;
CC       P04626; P42224: STAT1; NbExp=3; IntAct=EBI-641062, EBI-1057697;
CC       P04626; P40763: STAT3; NbExp=9; IntAct=EBI-641062, EBI-518675;
CC       P04626; P31948: STIP1; NbExp=2; IntAct=EBI-641062, EBI-1054052;
CC       P04626; Q7KZ85: SUPT6H; NbExp=2; IntAct=EBI-641062, EBI-2515547;
CC       P04626; P43405: SYK; NbExp=7; IntAct=EBI-641062, EBI-78302;
CC       P04626; Q9Y490: TLN1; NbExp=3; IntAct=EBI-641062, EBI-2462036;
CC       P04626; Q63HR2: TNS2; NbExp=4; IntAct=EBI-641062, EBI-949753;
CC       P04626; Q68CZ2: TNS3; NbExp=2; IntAct=EBI-641062, EBI-1220488;
CC       P04626; Q96D37: VAV1; NbExp=2; IntAct=EBI-641062, EBI-7875353;
CC       P04626; P52735: VAV2; NbExp=3; IntAct=EBI-641062, EBI-297549;
CC       P04626; O14980: XPO1; NbExp=3; IntAct=EBI-641062, EBI-355867;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:32381043};
CC       Single-pass type I membrane protein {ECO:0000255}. Cell projection,
CC       ruffle membrane {ECO:0000269|PubMed:34380438}; Single-pass type I
CC       membrane protein {ECO:0000255}. Note=Internalized from the cell
CC       membrane in response to EGF stimulation. {ECO:0000269|PubMed:32381043}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
CC       {ECO:0000269|PubMed:31138794, ECO:0000269|PubMed:33497358}; Single-pass
CC       type I membrane protein {ECO:0000255}. Early endosome
CC       {ECO:0000269|PubMed:31138794}. Cytoplasm, perinuclear region. Nucleus.
CC       Note=Translocation to the nucleus requires endocytosis, probably
CC       endosomal sorting and is mediated by importin beta-1/KPNB1. Also
CC       detected in VPS35-positive endosome-to-TGN retrograde vesicles
CC       (PubMed:31138794). {ECO:0000269|PubMed:31138794}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm. Nucleus.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Cytoplasm. Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=6;
CC       Name=1; Synonyms=ERBB2, HER2;
CC         IsoId=P04626-1; Sequence=Displayed;
CC       Name=2; Synonyms=CTF-611;
CC         IsoId=P04626-2; Sequence=VSP_039249;
CC       Name=3; Synonyms=CTF-687;
CC         IsoId=P04626-3; Sequence=VSP_039250;
CC       Name=4;
CC         IsoId=P04626-4; Sequence=VSP_039248;
CC       Name=5;
CC         IsoId=P04626-5; Sequence=VSP_054787;
CC       Name=6; Synonyms=B;
CC         IsoId=P04626-6; Sequence=VSP_055902, VSP_055903, VSP_055904;
CC   -!- TISSUE SPECIFICITY: Expressed in a variety of tumor tissues including
CC       primary breast tumors and tumors from small bowel, esophagus, kidney
CC       and mouth. {ECO:0000269|PubMed:15380516}.
CC   -!- PTM: Autophosphorylated. Autophosphorylation occurs in trans, i.e. one
CC       subunit of the dimeric receptor phosphorylates tyrosine residues on the
CC       other subunit (Probable). Ligand-binding increases phosphorylation on
CC       tyrosine residues (PubMed:27134172, PubMed:33497358). Signaling via
CC       SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007).
CC       Dephosphorylated by PTPN12 (PubMed:27134172).
CC       {ECO:0000269|PubMed:17554007, ECO:0000269|PubMed:27134172,
CC       ECO:0000269|PubMed:33497358, ECO:0000305}.
CC   -!- POLYMORPHISM: There are four alleles due to the variations in positions
CC       654 and 655. Allele B1 (Ile-654/Ile-655) has a frequency of 0.782;
CC       allele B2 (Ile-654/Val-655) has a frequency of 0.206; allele B3 (Val-
CC       654/Val-655) has a frequency of 0.012.
CC   -!- DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or malignant
CC       central nervous system neoplasms derived from glial cells. They
CC       comprise astrocytomas and glioblastoma multiforme that are derived from
CC       astrocytes, oligodendrogliomas derived from oligodendrocytes and
CC       ependymomas derived from ependymocytes. {ECO:0000269|PubMed:15457249}.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis.
CC   -!- DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer
CC       defines malignancies originating from ovarian tissue. Although many
CC       histologic types of ovarian tumors have been described, epithelial
CC       ovarian carcinoma is the most common form. Ovarian cancers are often
CC       asymptomatic and the recognized signs and symptoms, even of late-stage
CC       disease, are vague. Consequently, most patients are diagnosed with
CC       advanced disease. {ECO:0000269|PubMed:15457249,
CC       ECO:0000269|PubMed:17344846}. Note=The gene represented in this entry
CC       is involved in disease pathogenesis.
CC   -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting
CC       tissues of the lung. The most common form of lung cancer is non-small
CC       cell lung cancer (NSCLC) that can be divided into 3 major histologic
CC       subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung
CC       cancer. NSCLC is often diagnosed at an advanced stage and has a poor
CC       prognosis. {ECO:0000269|PubMed:15457249}. Note=The gene represented in
CC       this entry is involved in disease pathogenesis.
CC   -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which
CC       starts in the stomach, can spread to the esophagus or the small
CC       intestine, and can extend through the stomach wall to nearby lymph
CC       nodes and organs. It also can metastasize to other parts of the body.
CC       The term gastric cancer or gastric carcinoma refers to adenocarcinoma
CC       of the stomach that accounts for most of all gastric malignant tumors.
CC       Two main histologic types are recognized, diffuse type and intestinal
CC       type carcinomas. Diffuse tumors are poorly differentiated infiltrating
CC       lesions, resulting in thickening of the stomach. In contrast,
CC       intestinal tumors are usually exophytic, often ulcerating, and
CC       associated with intestinal metaplasia of the stomach, most often
CC       observed in sporadic disease. {ECO:0000269|PubMed:15457249,
CC       ECO:0000269|PubMed:17344846}. Note=The protein represented in this
CC       entry is involved in disease pathogenesis.
CC   -!- DISEASE: Note=Chromosomal aberrations involving ERBB2 may be a cause
CC       gastric cancer. Deletions within 17q12 region producing fusion
CC       transcripts with CDK12, leading to CDK12-ERBB2 fusion leading to
CC       truncated CDK12 protein not in-frame with ERBB2.
CC       {ECO:0000269|PubMed:21097718}.
CC   -!- DISEASE: Visceral neuropathy, familial, 2, autosomal recessive (VSCN2)
CC       [MIM:619465]: An autosomal recessive disorder characterized by
CC       intestinal dysmotility due to aganglionosis (Hirschsprung disease),
CC       hypoganglionosis, and/or chronic intestinal pseudoobstruction. Patients
CC       also show peripheral axonal neuropathy, hypotonia, mild developmental
CC       delay, unilateral ptosis, and sensorineural hearing loss.
CC       {ECO:0000269|PubMed:33497358}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative initiation at Met-
CC       611 of isoform 1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative initiation at Met-
CC       687 of isoform 1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ERBB2ID162ch17q11.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/erbb2/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=ERBB2 entry;
CC       URL="https://en.wikipedia.org/wiki/ERBB2";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AH001455; AAA35808.1; -; Genomic_DNA.
DR   EMBL; X03363; CAA27060.1; -; mRNA.
DR   EMBL; M11730; AAA75493.1; -; mRNA.
DR   EMBL; M12036; AAA35978.1; -; Genomic_DNA.
DR   EMBL; AY208911; AAO18082.1; -; Genomic_DNA.
DR   EMBL; AK295195; BAG58195.1; -; mRNA.
DR   EMBL; CH471152; EAW60597.1; -; Genomic_DNA.
DR   EMBL; BC167147; AAI67147.1; -; mRNA.
DR   EMBL; M16792; AAA58637.1; -; Genomic_DNA.
DR   EMBL; M16789; AAA58637.1; JOINED; Genomic_DNA.
DR   EMBL; M16790; AAA58637.1; JOINED; Genomic_DNA.
DR   EMBL; M16791; AAA58637.1; JOINED; Genomic_DNA.
DR   EMBL; KJ534964; AHW56604.1; -; mRNA.
DR   EMBL; L29395; AAA35809.1; -; Genomic_DNA.
DR   EMBL; M95667; AAC37531.1; -; Genomic_DNA.
DR   CCDS; CCDS32642.1; -. [P04626-1]
DR   CCDS; CCDS45667.1; -. [P04626-5]
DR   CCDS; CCDS74052.1; -. [P04626-4]
DR   PIR; A24571; A24571.
DR   RefSeq; NP_001005862.1; NM_001005862.2. [P04626-5]
DR   RefSeq; NP_001276865.1; NM_001289936.1. [P04626-4]
DR   RefSeq; NP_001276867.1; NM_001289938.1.
DR   RefSeq; NP_004439.2; NM_004448.3. [P04626-1]
DR   PDB; 1MFG; X-ray; 1.25 A; B=1247-1255.
DR   PDB; 1MFL; X-ray; 1.88 A; B=1247-1255.
DR   PDB; 1MW4; NMR; -; B=1135-1144.
DR   PDB; 1N8Z; X-ray; 2.52 A; C=23-629.
DR   PDB; 1QR1; X-ray; 2.40 A; C/F=654-662.
DR   PDB; 1S78; X-ray; 3.25 A; A/B=23-646.
DR   PDB; 2A91; X-ray; 2.50 A; A=22-530.
DR   PDB; 2JWA; NMR; -; A/B=641-684.
DR   PDB; 2KS1; NMR; -; A=641-684.
DR   PDB; 2L4K; NMR; -; B=1135-1144.
DR   PDB; 2N2A; NMR; -; A/B=644-700.
DR   PDB; 3BE1; X-ray; 2.90 A; A=23-646.
DR   PDB; 3H3B; X-ray; 2.45 A; A/B=23-214.
DR   PDB; 3MZW; X-ray; 2.90 A; A=23-646.
DR   PDB; 3N85; X-ray; 3.20 A; A=23-646.
DR   PDB; 3PP0; X-ray; 2.25 A; A/B=703-1029.
DR   PDB; 3RCD; X-ray; 3.21 A; A/B/C/D=713-1028.
DR   PDB; 3WLW; X-ray; 3.09 A; A/B=23-586.
DR   PDB; 3WSQ; X-ray; 3.50 A; A=23-586.
DR   PDB; 4GFU; X-ray; 2.00 A; F=1246-1252.
DR   PDB; 4HRL; X-ray; 2.55 A; C=24-219.
DR   PDB; 4HRM; X-ray; 3.20 A; A/C=24-219.
DR   PDB; 4HRN; X-ray; 2.65 A; C/D=529-625.
DR   PDB; 4NND; X-ray; 2.50 A; C/E/F/H=1109-1114.
DR   PDB; 5K33; X-ray; 3.30 A; C=23-629.
DR   PDB; 5KWG; X-ray; 4.30 A; C=23-653.
DR   PDB; 5MY6; X-ray; 2.25 A; A=24-645.
DR   PDB; 5O4G; X-ray; 3.00 A; C=23-628.
DR   PDB; 5OB4; NMR; -; A/B=641-684.
DR   PDB; 5TQS; X-ray; 1.88 A; E/F/G/H=1218-1228.
DR   PDB; 6ATT; X-ray; 3.77 A; A=23-652.
DR   PDB; 6BGT; X-ray; 2.70 A; C=1-652.
DR   PDB; 6J71; X-ray; 2.92 A; A=22-639.
DR   PDB; 6LBX; X-ray; 2.03 A; B=531-626.
DR   PDB; 6OGE; EM; 4.36 A; A=23-644.
DR   PDB; 7JXH; X-ray; 3.27 A; A/B/C/D/E/F/G/H=703-1024.
DR   PDB; 7MN5; EM; 2.93 A; B=1-1029.
DR   PDB; 7MN6; EM; 3.09 A; B=1-1029.
DR   PDB; 7MN8; EM; 3.45 A; B=1-1029.
DR   PDBsum; 1MFG; -.
DR   PDBsum; 1MFL; -.
DR   PDBsum; 1MW4; -.
DR   PDBsum; 1N8Z; -.
DR   PDBsum; 1QR1; -.
DR   PDBsum; 1S78; -.
DR   PDBsum; 2A91; -.
DR   PDBsum; 2JWA; -.
DR   PDBsum; 2KS1; -.
DR   PDBsum; 2L4K; -.
DR   PDBsum; 2N2A; -.
DR   PDBsum; 3BE1; -.
DR   PDBsum; 3H3B; -.
DR   PDBsum; 3MZW; -.
DR   PDBsum; 3N85; -.
DR   PDBsum; 3PP0; -.
DR   PDBsum; 3RCD; -.
DR   PDBsum; 3WLW; -.
DR   PDBsum; 3WSQ; -.
DR   PDBsum; 4GFU; -.
DR   PDBsum; 4HRL; -.
DR   PDBsum; 4HRM; -.
DR   PDBsum; 4HRN; -.
DR   PDBsum; 4NND; -.
DR   PDBsum; 5K33; -.
DR   PDBsum; 5KWG; -.
DR   PDBsum; 5MY6; -.
DR   PDBsum; 5O4G; -.
DR   PDBsum; 5OB4; -.
DR   PDBsum; 5TQS; -.
DR   PDBsum; 6ATT; -.
DR   PDBsum; 6BGT; -.
DR   PDBsum; 6J71; -.
DR   PDBsum; 6LBX; -.
DR   PDBsum; 6OGE; -.
DR   PDBsum; 7JXH; -.
DR   PDBsum; 7MN5; -.
DR   PDBsum; 7MN6; -.
DR   PDBsum; 7MN8; -.
DR   AlphaFoldDB; P04626; -.
DR   BMRB; P04626; -.
DR   SMR; P04626; -.
DR   BioGRID; 108376; 490.
DR   CORUM; P04626; -.
DR   DIP; DIP-8N; -.
DR   ELM; P04626; -.
DR   IntAct; P04626; 490.
DR   MINT; P04626; -.
DR   STRING; 9606.ENSP00000269571; -.
DR   BindingDB; P04626; -.
DR   ChEMBL; CHEMBL1824; -.
DR   DrugBank; DB08916; Afatinib.
DR   DrugBank; DB06021; AV-412.
DR   DrugBank; DB12267; Brigatinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB04988; IGN311.
DR   DrugBank; DB01259; Lapatinib.
DR   DrugBank; DB14967; Margetuximab.
DR   DrugBank; DB06366; Pertuzumab.
DR   DrugBank; DB11973; Tesevatinib.
DR   DrugBank; DB00072; Trastuzumab.
DR   DrugBank; DB05773; Trastuzumab emtansine.
DR   DrugBank; DB11652; Tucatinib.
DR   DrugBank; DB05944; Varlitinib.
DR   DrugBank; DB15035; Zanubrutinib.
DR   DrugCentral; P04626; -.
DR   GuidetoPHARMACOLOGY; 2019; -.
DR   MoonDB; P04626; Predicted.
DR   TCDB; 8.A.23.1.39; the basigin (basigin) family.
DR   CarbonylDB; P04626; -.
DR   GlyConnect; 1710; 13 N-Linked glycans (5 sites), 1 O-Linked glycan (1 site).
DR   GlyGen; P04626; 9 sites, 11 N-linked glycans (5 sites), 1 O-linked glycan (1 site), 1 Thr glycan (1 site).
DR   iPTMnet; P04626; -.
DR   PhosphoSitePlus; P04626; -.
DR   SwissPalm; P04626; -.
DR   BioMuta; ERBB2; -.
DR   DMDM; 119533; -.
DR   CPTAC; CPTAC-192; -.
DR   CPTAC; CPTAC-193; -.
DR   CPTAC; CPTAC-194; -.
DR   CPTAC; CPTAC-195; -.
DR   CPTAC; CPTAC-693; -.
DR   EPD; P04626; -.
DR   jPOST; P04626; -.
DR   MassIVE; P04626; -.
DR   MaxQB; P04626; -.
DR   PaxDb; P04626; -.
DR   PeptideAtlas; P04626; -.
DR   PRIDE; P04626; -.
DR   ProteomicsDB; 51718; -. [P04626-1]
DR   ProteomicsDB; 51719; -. [P04626-2]
DR   ProteomicsDB; 51720; -. [P04626-3]
DR   ProteomicsDB; 51721; -. [P04626-4]
DR   ABCD; P04626; 71 sequenced antibodies.
DR   Antibodypedia; 740; 6482 antibodies from 60 providers.
DR   CPTC; P04626; 4 antibodies.
DR   DNASU; 2064; -.
DR   Ensembl; ENST00000269571.10; ENSP00000269571.4; ENSG00000141736.14. [P04626-1]
DR   Ensembl; ENST00000406381.6; ENSP00000385185.2; ENSG00000141736.14. [P04626-5]
DR   Ensembl; ENST00000541774.5; ENSP00000446466.1; ENSG00000141736.14. [P04626-4]
DR   Ensembl; ENST00000584601.5; ENSP00000462438.1; ENSG00000141736.14. [P04626-5]
DR   GeneID; 2064; -.
DR   KEGG; hsa:2064; -.
DR   MANE-Select; ENST00000269571.10; ENSP00000269571.4; NM_004448.4; NP_004439.2.
DR   UCSC; uc060esv.1; human. [P04626-1]
DR   CTD; 2064; -.
DR   DisGeNET; 2064; -.
DR   GeneCards; ERBB2; -.
DR   HGNC; HGNC:3430; ERBB2.
DR   HPA; ENSG00000141736; Low tissue specificity.
DR   MalaCards; ERBB2; -.
DR   MIM; 137800; phenotype.
DR   MIM; 164870; gene.
DR   MIM; 167000; phenotype.
DR   MIM; 211980; phenotype.
DR   MIM; 613659; phenotype.
DR   MIM; 619465; phenotype.
DR   neXtProt; NX_P04626; -.
DR   OpenTargets; ENSG00000141736; -.
DR   Orphanet; 388; Hirschsprung disease.
DR   PharmGKB; PA27844; -.
DR   VEuPathDB; HostDB:ENSG00000141736; -.
DR   eggNOG; KOG1025; Eukaryota.
DR   GeneTree; ENSGT00940000158232; -.
DR   InParanoid; P04626; -.
DR   OMA; YVSDRHC; -.
DR   OrthoDB; 81952at2759; -.
DR   PhylomeDB; P04626; -.
DR   TreeFam; TF106002; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P04626; -.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1251932; PLCG1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1306955; GRB7 events in ERBB2 signaling.
DR   Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling.
DR   Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling.
DR   Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling.
DR   Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling.
DR   Reactome; R-HSA-8866910; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors.
DR   Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2.
DR   Reactome; R-HSA-9652282; Drug-mediated inhibition of ERBB2 signaling.
DR   Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants.
DR   Reactome; R-HSA-9665233; Resistance of ERBB2 KD mutants to trastuzumab.
DR   Reactome; R-HSA-9665244; Resistance of ERBB2 KD mutants to sapitinib.
DR   Reactome; R-HSA-9665245; Resistance of ERBB2 KD mutants to tesevatinib.
DR   Reactome; R-HSA-9665246; Resistance of ERBB2 KD mutants to neratinib.
DR   Reactome; R-HSA-9665247; Resistance of ERBB2 KD mutants to osimertinib.
DR   Reactome; R-HSA-9665249; Resistance of ERBB2 KD mutants to afatinib.
DR   Reactome; R-HSA-9665250; Resistance of ERBB2 KD mutants to AEE788.
DR   Reactome; R-HSA-9665251; Resistance of ERBB2 KD mutants to lapatinib.
DR   Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants.
DR   Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants.
DR   Reactome; R-HSA-9665737; Drug resistance in ERBB2 TMD/JMD mutants.
DR   SignaLink; P04626; -.
DR   SIGNOR; P04626; -.
DR   BioGRID-ORCS; 2064; 91 hits in 1117 CRISPR screens.
DR   ChiTaRS; ERBB2; human.
DR   EvolutionaryTrace; P04626; -.
DR   GeneWiki; HER2/neu; -.
DR   GenomeRNAi; 2064; -.
DR   Pharos; P04626; Tclin.
DR   PRO; PR:P04626; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P04626; protein.
DR   Bgee; ENSG00000141736; Expressed in lower esophagus mucosa and 184 other tissues.
DR   ExpressionAtlas; P04626; baseline and differential.
DR   Genevisible; P04626; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0010008; C:endosome membrane; IDA:UniProtKB.
DR   GO; GO:0038143; C:ERBB3:ERBB2 complex; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0044214; C:spanning component of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043125; F:ErbB-3 class receptor binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0001042; F:RNA polymerase I core binding; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:BHF-UCL.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:MGI.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IMP:UniProtKB.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0007167; P:enzyme-linked receptor protein signaling pathway; TAS:ProtInc.
DR   GO; GO:0038134; P:ERBB2-EGFR signaling pathway; IDA:MGI.
DR   GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; IEA:Ensembl.
DR   GO; GO:0038135; P:ERBB2-ERBB4 signaling pathway; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0033080; P:immature T cell proliferation in thymus; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0008045; P:motor neuron axon guidance; IEA:Ensembl.
DR   GO; GO:0042552; P:myelination; IEA:Ensembl.
DR   GO; GO:0033088; P:negative regulation of immature T cell proliferation in thymus; IEA:Ensembl.
DR   GO; GO:0007528; P:neuromuscular junction development; IEA:Ensembl.
DR   GO; GO:0030182; P:neuron differentiation; IBA:GO_Central.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0007422; P:peripheral nervous system development; IEA:Ensembl.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IDA:BHF-UCL.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0030307; P:positive regulation of cell growth; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IBA:GO_Central.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; ISS:BHF-UCL.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0090314; P:positive regulation of protein targeting to membrane; IDA:UniProtKB.
DR   GO; GO:0045943; P:positive regulation of transcription by RNA polymerase I; IMP:UniProtKB.
DR   GO; GO:0045727; P:positive regulation of translation; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0045765; P:regulation of angiogenesis; NAS:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0032886; P:regulation of microtubule-based process; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; IDA:BHF-UCL.
DR   CDD; cd00064; FU; 3.
DR   DisProt; DP01484; -.
DR   Gene3D; 3.80.20.20; -; 2.
DR   IDEAL; IID00293; -.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR032778; GF_recep_IV.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR036941; Rcpt_L-dom_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF14843; GF_recep_IV; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000619; TyrPK_EGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative initiation; Alternative splicing;
KW   ATP-binding; Cell membrane; Cell projection; Chromosomal rearrangement;
KW   Cytoplasm; Disease variant; Disulfide bond; Endosome; Glycoprotein; Kinase;
KW   Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; Receptor;
KW   Reference proteome; Signal; Transcription; Transcription regulation;
KW   Transferase; Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL          1..22
FT                   /evidence="ECO:0000255"
FT   CHAIN           23..1255
FT                   /note="Receptor tyrosine-protein kinase erbB-2"
FT                   /id="PRO_0000016669"
FT   TOPO_DOM        23..652
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        653..675
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        676..1255
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          720..987
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          676..689
FT                   /note="Required for interaction with KPNB1 and EEA1"
FT                   /evidence="ECO:0000269|PubMed:16314522"
FT   REGION          1035..1179
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1195..1197
FT                   /note="Interaction with PIK3C2B"
FT                   /evidence="ECO:0000305"
FT   REGION          1196..1255
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           676..689
FT                   /note="Nuclear localization signal"
FT   COMPBIAS        1142..1157
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        845
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         726..734
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         753
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         182
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         877
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000305|PubMed:32381043"
FT   MOD_RES         1054
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1078
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P06494"
FT   MOD_RES         1083
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1107
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         1112
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:27134172"
FT   MOD_RES         1139
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:27134172"
FT   MOD_RES         1151
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1166
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1196
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:27134172,
FT                   ECO:0000305|PubMed:32381043"
FT   MOD_RES         1248
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:17554007,
FT                   ECO:0000269|PubMed:27134172, ECO:0007744|PubMed:17081983"
FT   CARBOHYD        68
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:20696930,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3MZW"
FT   CARBOHYD        124
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        187
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255, ECO:0007744|PDB:1N8Z,
FT                   ECO:0007744|PDB:1S78, ECO:0007744|PDB:2A91,
FT                   ECO:0007744|PDB:3N85"
FT   CARBOHYD        259
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:15093539,
FT                   ECO:0000269|PubMed:19299620, ECO:0000269|PubMed:20696930,
FT                   ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3MZW,
FT                   ECO:0007744|PDB:3N85"
FT   CARBOHYD        530
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:15093539,
FT                   ECO:0000269|PubMed:19299620, ECO:0007744|PDB:1S78"
FT   CARBOHYD        571
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:20696930,
FT                   ECO:0007744|PDB:3MZW"
FT   CARBOHYD        629
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        26..53
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW,
FT                   ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW,
FT                   ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL,
FT                   ECO:0007744|PDB:4HRM"
FT   DISULFID        162..192
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW,
FT                   ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW,
FT                   ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL,
FT                   ECO:0007744|PDB:4HRM"
FT   DISULFID        195..204
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW,
FT                   ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW,
FT                   ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL,
FT                   ECO:0007744|PDB:4HRM"
FT   DISULFID        199..212
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3H3B, ECO:0007744|PDB:3MZW,
FT                   ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW,
FT                   ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRL,
FT                   ECO:0007744|PDB:4HRM"
FT   DISULFID        220..227
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85,
FT                   ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ"
FT   DISULFID        224..235
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85,
FT                   ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ"
FT   DISULFID        236..244
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85,
FT                   ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ"
FT   DISULFID        240..252
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85,
FT                   ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ"
FT   DISULFID        255..264
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85,
FT                   ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ"
FT   DISULFID        268..295
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85,
FT                   ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ"
FT   DISULFID        299..311
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85,
FT                   ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ"
FT   DISULFID        315..331
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85,
FT                   ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ"
FT   DISULFID        334..338
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85,
FT                   ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ"
FT   DISULFID        342..367
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85,
FT                   ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ"
FT   DISULFID        475..504
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85,
FT                   ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ"
FT   DISULFID        511..520
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85,
FT                   ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ"
FT   DISULFID        515..528
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:2A91, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3MZW, ECO:0007744|PDB:3N85,
FT                   ECO:0007744|PDB:3WLW, ECO:0007744|PDB:3WSQ"
FT   DISULFID        531..540
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW,
FT                   ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW,
FT                   ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN"
FT   DISULFID        544..560
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW,
FT                   ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW,
FT                   ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN"
FT   DISULFID        563..576
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW,
FT                   ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW,
FT                   ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN"
FT   DISULFID        567..584
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW,
FT                   ECO:0007744|PDB:3N85, ECO:0007744|PDB:3WLW,
FT                   ECO:0007744|PDB:3WSQ, ECO:0007744|PDB:4HRN"
FT   DISULFID        587..596
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:1S78,
FT                   ECO:0007744|PDB:3BE1, ECO:0007744|PDB:3MZW,
FT                   ECO:0007744|PDB:3N85, ECO:0007744|PDB:4HRN"
FT   DISULFID        600..623
FT                   /evidence="ECO:0007744|PDB:1N8Z, ECO:0007744|PDB:3BE1,
FT                   ECO:0007744|PDB:3N85"
FT   DISULFID        626..634
FT                   /evidence="ECO:0007744|PDB:3N85"
FT   DISULFID        630..642
FT                   /evidence="ECO:0007744|PDB:3N85"
FT   VAR_SEQ         1..686
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_039250"
FT   VAR_SEQ         1..610
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_039249"
FT   VAR_SEQ         1..30
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_054787"
FT   VAR_SEQ         1..23
FT                   /note="MELAALCRWGLLLALLPPGAAST -> MPRGSWKP (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_039248"
FT   VAR_SEQ         633..648
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:24722188"
FT                   /id="VSP_055902"
FT   VAR_SEQ         771..883
FT                   /note="AYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDL
FT                   LNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADG
FT                   GK -> TISNLFSNFAPRGPSACCEPTCWCHSGKGQDSLPREEWGRQRRFCLWGCRGEP
FT                   RVLDTPGRSCPSAPPSSCLQPSLRQPLLLGPGPTRAGGSTQHLQRDTYGREPRVPGSGR
FT                   ASVNQKAKSAEALMCPQGAGKA (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:24722188"
FT                   /id="VSP_055903"
FT   VAR_SEQ         884..1255
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:24722188"
FT                   /id="VSP_055904"
FT   VARIANT         452
FT                   /note="W -> C (in dbSNP:rs4252633)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_016317"
FT   VARIANT         654
FT                   /note="I -> V (in allele B3; dbSNP:rs1801201)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:8095488"
FT                   /id="VAR_004077"
FT   VARIANT         655
FT                   /note="I -> V (in allele B2 and allele B3;
FT                   dbSNP:rs1136201)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:8095488, ECO:0000269|Ref.3"
FT                   /id="VAR_004078"
FT   VARIANT         710
FT                   /note="A -> V (in VSCN2; almost complete loss of ERBB2 and
FT                   ERBB3 phosphorylation in the presence or in the absence of
FT                   NRG1 stimulation, suggesting alteration of downstream
FT                   signaling; does not affect the subcellular localization at
FT                   the cell membrane)"
FT                   /evidence="ECO:0000269|PubMed:33497358"
FT                   /id="VAR_086107"
FT   VARIANT         755
FT                   /note="L -> P (in LNCR; somatic mutation; unknown
FT                   pathological significance; dbSNP:rs121913469)"
FT                   /evidence="ECO:0000269|PubMed:15457249"
FT                   /id="VAR_055432"
FT   VARIANT         768
FT                   /note="L -> S (in dbSNP:rs56366519)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042097"
FT   VARIANT         774
FT                   /note="M -> MAYVM (in LNCR; somatic mutation; unknown
FT                   pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:15457249"
FT                   /id="VAR_055433"
FT   VARIANT         776
FT                   /note="G -> S (in GASC; somatic mutation; unknown
FT                   pathological significance; dbSNP:rs28933369)"
FT                   /evidence="ECO:0000269|PubMed:15457249,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042098"
FT   VARIANT         779
FT                   /note="S -> SVGS (in LNCR; somatic mutation; unknown
FT                   pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:15457249"
FT                   /id="VAR_055434"
FT   VARIANT         857
FT                   /note="N -> S (in OC; somatic mutation; unknown
FT                   pathological significance; dbSNP:rs28933370)"
FT                   /evidence="ECO:0000269|PubMed:15457249,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042099"
FT   VARIANT         914
FT                   /note="E -> K (in GLM; somatic mutation; unknown
FT                   pathological significance; dbSNP:rs28933368)"
FT                   /evidence="ECO:0000269|PubMed:15457249"
FT                   /id="VAR_055435"
FT   VARIANT         1170
FT                   /note="P -> A (in dbSNP:rs1058808)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:2999974, ECO:0000269|PubMed:8104414,
FT                   ECO:0000269|Ref.3"
FT                   /id="VAR_016318"
FT   VARIANT         1216
FT                   /note="A -> D (in dbSNP:rs55943169)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042100"
FT   MUTAGEN         317..318
FT                   /note="LH->AA: Reduces dimerization with ERBB3."
FT                   /evidence="ECO:0000269|PubMed:15093539"
FT   MUTAGEN         611
FT                   /note="M->A: Prevents synthesis of isoform 2."
FT                   /evidence="ECO:0000269|PubMed:16794579"
FT   MUTAGEN         687
FT                   /note="M->A: Prevents synthesis of isoform 3."
FT                   /evidence="ECO:0000269|PubMed:16794579"
FT   MUTAGEN         706
FT                   /note="M->A: No effect on isoform production."
FT                   /evidence="ECO:0000269|PubMed:16794579"
FT   MUTAGEN         712
FT                   /note="M->A: No effect on isoform production."
FT                   /evidence="ECO:0000269|PubMed:16794579"
FT   STRAND          25..27
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   HELIX           39..50
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          55..64
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   HELIX           72..74
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          79..82
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          84..88
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          92..95
FT                   /evidence="ECO:0007829|PDB:3H3B"
FT   TURN            109..111
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          112..117
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   TURN            130..132
FT                   /evidence="ECO:0007829|PDB:3H3B"
FT   STRAND          139..141
FT                   /evidence="ECO:0007829|PDB:3H3B"
FT   STRAND          147..150
FT                   /evidence="ECO:0007829|PDB:2A91"
FT   STRAND          152..156
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   TURN            164..166
FT                   /evidence="ECO:0007829|PDB:3H3B"
FT   HELIX           169..172
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   HELIX           175..177
FT                   /evidence="ECO:0007829|PDB:1N8Z"
FT   STRAND          182..184
FT                   /evidence="ECO:0007829|PDB:3H3B"
FT   HELIX           200..202
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          204..208
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   HELIX           209..211
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          217..219
FT                   /evidence="ECO:0007829|PDB:1N8Z"
FT   HELIX           221..223
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          227..231
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   HELIX           232..234
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          240..248
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          251..260
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          263..267
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          271..274
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   TURN            276..278
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          281..283
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   TURN            284..286
FT                   /evidence="ECO:0007829|PDB:6J71"
FT   STRAND          289..291
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          294..298
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          303..305
FT                   /evidence="ECO:0007829|PDB:1N8Z"
FT   STRAND          309..314
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          319..323
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          325..327
FT                   /evidence="ECO:0007829|PDB:3MZW"
FT   STRAND          329..333
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          335..337
FT                   /evidence="ECO:0007829|PDB:2A91"
FT   HELIX           348..350
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   TURN            358..360
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   HELIX           361..364
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          368..376
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   HELIX           378..382
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   HELIX           385..387
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   HELIX           394..400
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          405..408
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          410..413
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   HELIX           423..425
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          430..435
FT                   /evidence="ECO:0007829|PDB:3WLW"
FT   TURN            438..440
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          441..447
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          463..469
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   TURN            476..479
FT                   /evidence="ECO:0007829|PDB:7MN5"
FT   HELIX           482..485
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          488..490
FT                   /evidence="ECO:0007829|PDB:6J71"
FT   STRAND          493..499
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   HELIX           501..506
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   TURN            507..509
FT                   /evidence="ECO:0007829|PDB:3N85"
FT   HELIX           516..518
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   STRAND          520..524
FT                   /evidence="ECO:0007829|PDB:5MY6"
FT   HELIX           525..527
FT                   /evidence="ECO:0007829|PDB:2A91"
FT   STRAND          532..536
FT                   /evidence="ECO:0007829|PDB:6LBX"
FT   STRAND          539..542
FT                   /evidence="ECO:0007829|PDB:6LBX"
FT   STRAND          545..551
FT                   /evidence="ECO:0007829|PDB:6LBX"
FT   STRAND          553..556
FT                   /evidence="ECO:0007829|PDB:6LBX"
FT   STRAND          559..562
FT                   /evidence="ECO:0007829|PDB:6LBX"
FT   STRAND          565..567
FT                   /evidence="ECO:0007829|PDB:3WSQ"
FT   STRAND          571..573
FT                   /evidence="ECO:0007829|PDB:6LBX"
FT   STRAND          575..580
FT                   /evidence="ECO:0007829|PDB:6LBX"
FT   STRAND          583..592
FT                   /evidence="ECO:0007829|PDB:6LBX"
FT   STRAND          595..599
FT                   /evidence="ECO:0007829|PDB:6LBX"
FT   STRAND          602..604
FT                   /evidence="ECO:0007829|PDB:6J71"
FT   STRAND          615..617
FT                   /evidence="ECO:0007829|PDB:1N8Z"
FT   STRAND          621..625
FT                   /evidence="ECO:0007829|PDB:1N8Z"
FT   STRAND          630..632
FT                   /evidence="ECO:0007829|PDB:6J71"
FT   STRAND          635..637
FT                   /evidence="ECO:0007829|PDB:6J71"
FT   HELIX           651..678
FT                   /evidence="ECO:0007829|PDB:2JWA"
FT   HELIX           684..690
FT                   /evidence="ECO:0007829|PDB:2N2A"
FT   HELIX           691..697
FT                   /evidence="ECO:0007829|PDB:2N2A"
FT   HELIX           717..719
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   STRAND          720..728
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   STRAND          730..739
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   STRAND          748..755
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   HELIX           761..774
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   STRAND          785..799
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   HELIX           806..812
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   TURN            814..816
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   HELIX           819..838
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   HELIX           848..850
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   STRAND          851..855
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   STRAND          858..861
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   HELIX           886..888
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   HELIX           891..896
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   HELIX           901..916
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   TURN            922..925
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   HELIX           928..930
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   HELIX           931..936
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   HELIX           949..958
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   HELIX           963..965
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   HELIX           969..980
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   HELIX           983..986
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   HELIX           989..992
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   HELIX           1003..1007
FT                   /evidence="ECO:0007829|PDB:3PP0"
FT   STRAND          1140..1142
FT                   /evidence="ECO:0007829|PDB:1MW4"
SQ   SEQUENCE   1255 AA;  137910 MW;  39E9DFDA04DCF962 CRC64;
     MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVQGNL
     ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR IVRGTQLFED NYALAVLDNG
     DPLNNTTPVT GASPGGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA
     LTLIDTNRSR ACHPCSPMCK GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC
     AAGCTGPKHS DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
     YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL REVRAVTSAN
     IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF ETLEEITGYL YISAWPDSLP
     DLSVFQNLQV IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIHH NTHLCFVHTV
     PWDQLFRNPH QALLHTANRP EDECVGEGLA CHQLCARGHC WGPGPTQCVN CSQFLRGQEC
     VEECRVLQGL PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
     PSGVKPDLSY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP LTSIISAVVG
     ILLVVVLGVV FGILIKRRQQ KIRKYTMRRL LQETELVEPL TPSGAMPNQA QMRILKETEL
     RKVKVLGSGA FGTVYKGIWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP
     YVSRLLGICL TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWCMQIA KGMSYLEDVR
     LVHRDLAARN VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPIKWMA LESILRRRFT
     HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM
     IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL DSTFYRSLLE DDDMGDLVDA
     EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS STRSGGGDLT LGLEPSEEEA PRSPLAPSEG
     AGSDVFDGDL GMGAAKGLQS LPTHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV
     NQPDVRPQPP SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ
     GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG LDVPV
//
